Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia

Fundació Clínic per a la Recerca Biomèdica0 sites100 target enrollmentApril 13, 2020

Overview

No summary available.

Registry

who.int

Start Date

April 13, 2020

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Fundació Clínic per a la Recerca Biomèdica

•1\. Age \= 18 years old.
•2\. Hospitalized patient (or documentation of a hospitalization plan if the patient is in an emergency department) with illness of more than 5 days of duration with evidence of pneumonia by chest radiography / tomography computed chest and meets at least one of the following requirements:
•a) Non\-critical patient with pneumonia in radiological progression and / or
•b) Patient with progressive respiratory failure at the last 24\-48 hours.
•3\. Laboratory confirmed SARS\-CoV\-2 infection (by PCR) or other commercialized analysis or public health in any sample collected 4 days before the randomization or COVID\-19 criteria following the defined diagnostic criteria at that time in the center.
•4\. Patient with a maximum O2 support of 35%
•5\. Be willing and able to comply with the study related procedures / evaluations.
•6\. Women of childbearing potential \* should have a negative serum pregnancy test before enrollment in the study and must commit to using methods highly effective contraceptives (intrauterine device, bilateral tubal occlusion, vasectomized couple and sexual abstinence).
•7\. Written informed consent. In case of inability of the patient to sign the informed consent, a verbal informed consent from the legal representative or family witness (or failing this, an impartial witness outside the investigator team) will be obtained by phone.
•When circumstances so allow, participants should sign the consent form.

•1\. Patient who, in the investigator's opinion, is unlikely to survive\> 48 hours after the inclusion in the study.
•2\. Presence of any of the following abnormal analytical values at the time of the inclusion in the study:
•\- absolute neutrophil count (RAN) less than 2000 / mm3;
•\- AST or ALT\> 5 times the ULN;
•\- platelets \<50,000 per mm3\.
•3\. In active treatment with immunosuppressants or previous prolonged treatment (more 3 months) of oral corticosteroids for a disease not related to COVID\-19 at a dose greater than 10 mg of prednisone or equivalent per day.
•4\. Known active tuberculosis (TB) or known history of TB uncompleted treatment.
•5\. Patients with active systemic bacterial and / or fungal infections.
•6\. Participants who, at the investigator's discretion, are not eligible to participate, regardless of the reason, including medical or clinical conditions, or participants potentially at risk of not following study procedures.
•7\. Patients who do not have entry criteria in the Intensive Care Unit.